HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ICCC

ImmuCell Corporation (NASDAQ)

Healthcare — Biotechnology

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

None
$11.13
$-0.06 (-0.58%)
Sign in to add ICCC to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$99.51M
P/E Ratio (TTM)-
Forward P/E-100.00
EPS (TTM)$-0.07
Dividend Yield-
Profit Margin-1.82%
Revenue Growth28.40%
ROE-1.88%
Debt/Equity43.86
Recommendation None
Analyst Target-
Analysts-
Indexes NASDAQ

Technical Indicators

RSI (14)77.6
Beta0.57
SMA 20-
SMA 40-
52-Week High$11.16
52-Week Low$4.52
50-Day Avg$9.32
200-Day Avg$6.99
Avg Volume30.7K
Volume23.4K

Performance Analysis

NEUTRAL

ICCC presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($11.16), which may indicate limited upside.
- RSI at 77.6 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 28.4% year-over-year.
- Operating at a loss with -1.8% margin.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:14 UTC

Back to Screener Export Report